Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. CBRS
4. HTZ
5. FDX
6. USO
7. SPY
8. LAES
9. KBH
10. HON

Go back to Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
(NYSE: BHVN) Delayed: 14.96 +0.18 (1.22%)
Previous Close $14.78    52 Week High $ 
Open $14.78    52 Week Low $ 
Day High $15.23    P/E N/A 
Day Low $14.50    EPS $ 
Volume 2,258,165